{
    "clinical_study": {
        "@rank": "131336", 
        "brief_summary": {
            "textblock": "To determine the proportion of patients whose plasma HIV-1 RNA level falls below the level\n      of detection (< 400 copies/ml) at week 16 and 24 of study therapy. To determine the absolute\n      change in plasma HIV-1 RNA and in absolute CD4 cell count during the 24 weeks of study\n      treatment. To collect safety data on the treatment regimens. To determine the percentage of\n      patients without SQV soft gel capsules resistance-associated mutations at week 24."
        }, 
        "brief_title": "A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients are randomized to receive 1 of 3 study regimens: Group A - Saquinavir (SQV) soft\n      gel capsules (sgc) plus 2 reverse transcriptase inhibitors (RTIs), Group B - SQV sgc plus\n      delavirdine plus RTI, and Group C - SQV sgc plus nelfinavir plus RTI (or SQV sgc plus\n      ritonavir plus 2 RTIs)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  HIV RNA >= 5000 copies/ml by Amplicor assay.\n\n          -  Signed, informed consent from parent or legal guardian for patients less than 18\n             years old.\n\n        Previous treatment with antiretrovirals."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": "375", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002178", 
            "org_study_id": "229J", 
            "secondary_id": "NR15539"
        }, 
        "intervention": [
            {
                "intervention_name": "Ritonavir", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Nelfinavir mesylate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Saquinavir", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Delavirdine mesylate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "HIV Protease Inhibitors", 
                "Saquinavir", 
                "Ritonavir", 
                "Nelfinavir", 
                "Reverse Transcriptase Inhibitors", 
                "Delavirdine"
            ]
        }, 
        "keyword": [
            "HIV-1", 
            "Drug Therapy, Combination", 
            "HIV Protease Inhibitors", 
            "RNA, Viral", 
            "Dosage Forms", 
            "Saquinavir", 
            "Reverse Transcriptase Inhibitors", 
            "Anti-HIV Agents", 
            "Viral Load"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90048"
                    }, 
                    "name": "Dr Charles Farthing"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brookline", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02445"
                    }, 
                    "name": "Community Research Initiative"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "reference": {
            "PMID": "11364377", 
            "citation": "Cadman J. Roche brings new formulation of saquinavir to FDA. Food and Drug Administration. GMHC Treat Issues. 1997 Apr-May;11(4/5):8. No abstract available."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002178"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 1997"
    }, 
    "geocoordinates": {
        "Community Research Initiative": "42.332 -71.121", 
        "Dr Charles Farthing": "34.052 -118.244"
    }
}